What is Amarin’s view on the reliability of third-party script reporting services?
What is Amarin's perspective on the results of Novartis' CANTOS study on canakinumab (Updated March 19, 2019)
其实呢。200或600到现在的1800就9倍或3倍。而且要6到3年。。。
如果不是动不动就往下跌,估计大家也都拿得住,哪怕随着大盘也行,大家也稍微安心点。否则,很容易几个猛烈震荡就震出去了,尤其是融资的,肯定是希望快点BO啊。
主要大部分人都想快BO算了。